Limitation of complement activation by perfluorocarbon emulsions: superiority of lecithin-emulsified preparations.
暂无分享,去创建一个
[1] K. Waxman,et al. Pulmonary complications after Fluosol administration to patients with life‐threatening blood loss , 1985, Critical care medicine.
[2] F. Port,et al. Complement activation and hypersensitivity reactions to dialysis membranes. , 1984, The New England journal of medicine.
[3] H. Jacob,et al. Symptoms and activation of granulocytes and complement with two dialysis membranes. , 1983, Kidney international.
[4] A. Cheung,et al. Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes. , 1983, Kidney international.
[5] L. Fink,et al. Effects of perfluorochemical on phagocytic function of leukocytes , 1983, Transfusion.
[6] D. Camarillo,et al. The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, Fluosol-DA. , 1982, The New England journal of medicine.
[7] G. Vercellotti,et al. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis , 1982 .
[8] H. Jacob,et al. Complement-induced granulocyte aggregation in vivo. , 1981, The American journal of pathology.
[9] D. Stroncek,et al. Complement activation and neutropenia occurring during cardiopulmonary bypass. , 1981, The Journal of thoracic and cardiovascular surgery.
[10] F. Iwaya,et al. Clinical use of a blood substitute. , 1980, The New England journal of medicine.
[11] H. Jacob,et al. Granulocyte aggregometry: a sensitive technique for the detection of C5a and complement activation. , 1980, Blood.
[12] L. J. Weaver,et al. ASSOCIATION OF COMPLEMENT ACTIVATION AND ELEVATED PLASMA-C5a WITH ADULT RESPIRATORY DISTRESS SYNDROME Pathophysiological Relevance and Possible Prognostic Value , 1980, The Lancet.
[13] J. White,et al. Corticosteroids inhibit complement-induced granulocyte aggregation. A possible mechanism for their efficacy in shock states. , 1979, The Journal of clinical investigation.
[14] J. White,et al. Complement (C5-a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia. , 1977, The Journal of clinical investigation.
[15] A. Dalmasso,et al. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. , 1977, The Journal of clinical investigation.
[16] R S Kronenberg,et al. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. , 1977, The New England journal of medicine.
[17] H. Jacob,et al. Mechanism of Anti-Complementary Activity of Corticosteroids in Vivo: Possible Relevance in Endotoxin Shock , 1977, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[18] Cornish Cb,et al. MEDICAL TREATMENT OF OSTEOARTHRITIS. , 1965, Lancet.
[19] D. Hammerschmidt. Clinical utility of complement anaphylatoxin assays. , 1986, Complement.
[20] F. Cerra,et al. Use of a whole blood substitute, Fluosol-DA 20%, after massive postpartum hemorrhage. , 1985, Obstetrics and gynecology.
[21] D. Stroncek,et al. Effect of dialyzer reuse on complement activation and neutropenia in hemodialysis. , 1984, The Journal of laboratory and clinical medicine.
[22] J. Williams,et al. Amniotic fluid activates complement. A role in amniotic fluid embolism syndrome? , 1984, The Journal of laboratory and clinical medicine.
[23] D. Chenoweth. Biocompatibility of hemodialysis membranes: evaluation with C3a anaphylatoxin radioimmunoassays , 1984 .
[24] H. Ohyanagi,et al. Clinical studies of a perfluorochemical whole blood substitute (Fluosol-DA) Summary of 186 cases. , 1982, Annals of surgery.